Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.
The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.
The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.
Verona Pharma shares were fractionally higher in recent Friday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。